SINGLE-CENTER EXPERIENCE: Immunosuppressive Therapy as Frontline Treatment for 33 Children with Acquired Severe Aplastic Anemia

REFERENCES

• Young N S. Pathophysiologic mechanisms in acquired aplastic anemia. Hematology Am Soc Hematol Educ Program 2006; 72–77
   PubMedGoogle Scholar
• Maury S, Balère-Appert M L, Chir Z, et al. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica 2007; 92: 589–596
   PubMed Web of Science ®Google Scholar
• Armand P, Antin J H. Allogeneic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transplant. 2007; 13: 505–516
   PubMedGoogle Scholar
• Viollier R, Passweg J, Gregor M, et al. Quality-adjusted survival analysis shows differences in outcome after immunosuppression or bone marrow transplantation in aplastic anemia. Ann Hematol. 2005; 84: 47–55
   PubMed Web of Science ®Google Scholar
• Führer M, Rampf U, Baumann I, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005; 106: 2102–2104
   PubMed Web of Science ®Google Scholar
• Teramura M, Kimura A, Iwase S, et al. Treatment of severe aplastic anemia with antilymphocyte globulin and cyclosporine A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood. 2007; 110: 1756–1761
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Nunez O, Young N S. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplstic anemia. Br J Haematol. 2006; 133: 622–627
   PubMed Web of Science ®Google Scholar
• Tichelli A, Socie G, Henry-Amar M, et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party. Ann Intern Med. 1999; 130: 193–201
   PubMed Web of Science ®Google Scholar
• Saracco P, Quarello P, Iori A P, et al. Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up. Br J Haematol. 2008; 140: 197–205
   PubMed Web of Science ®Google Scholar
• Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000; 96: 2049–2054
   PubMed Web of Science ®Google Scholar
• Gluckman E, Rokicka-Milewska R, Hann I, et al. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol. 2002; 119: 1075–1082
   PubMed Web of Science ®Google Scholar
• Marsh J. Making therapeutic decisions in adults with aplastic anemia. Hematology Am Soc Hematol Educ Program., 2006: 78–85
   Google Scholar
• Eapen M, Ramsay N K, Mertens A C, et al. Late outcomes after bone marrow transplant for aplastic anaemia. Br J Haematol. 2000; 111: 754–760
   PubMed Web of Science ®Google Scholar
• Kojima S, Horibe K, Inaba J, et al. Long-term outcome of acquired aplastic anaemia in children: comparision between immunosuppressive therapy and bone marrow transplantation. Br J Haematol. 2000; 111: 321–328
   PubMed Web of Science ®Google Scholar
• Ades L, Mary J Y, Robin M, et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood. 2004; 103: 2490–2497
   PubMed Web of Science ®Google Scholar
• Kobayashi R, Yabe H, Hara J, et al. Preceding immunosuppressive therapy with antithymocyte globulin and cyclosporin increases the incidence of graft rejection in children with aplastic anemia who underwent allogeneic bone marrow. Br J Haematol. 2006; 135: 693–696
   PubMed Web of Science ®Google Scholar
• Benesch M, Urban C, Sykora K W, et al. Transplantation of highly purified CD34+ progenitor cells from alternative donors in children with refractory severe aplastic anaemia. Br J Haematol. 2004; 125: 58–63
   PubMed Web of Science ®Google Scholar
• Davies J K, Guinan E C. An update on the management of severe idiopathic aplastic anaemia in children. Br J Haematol. 2007; 136: 549–564
   PubMed Web of Science ®Google Scholar
• Locasciulli A, Oneto R. Bacigalupo A, et al. Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplant Group. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood Marrow Transplantation (EBMT). Haematologica. 2007; 92: 11–18
   PubMed Web of Science ®Google Scholar
• Abdelkefi A, Ben Othman T, Ladeb S, et al. Bone marrow transplantation for patients with acquired severe aplastic anemia using cyclophosphamide and antithymocyte globulin: the experience from a single center. Hematol J. 2003; 4: 208–213
   PubMedGoogle Scholar
• Pongtanakul B, Das P K, Charpentier K, Dror Y. Outcome of children with aplastic anemia treated with immunosuppressive therapy. Pediatr Blood Cancer. 2008; 50: 52–57
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüelles G J, Gómez-Rangel J D. Long-term results of the immunosuppressive treatment of patients with severe acquired aplastic anemia: a single institution study. Acta Haematol. 2003; 110: 184–187
   PubMed Web of Science ®Google Scholar
• Kojima S, Ohara A, Tsuchida M, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood. 2002; 100: 786–790
   PubMed Web of Science ®Google Scholar